Drugs / MK-1602
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01657370 | Aug → Nov 2012 | migraine disorder | Allergan | Completed | No outcome recorded |
| Phase 2 | NCT01613248 | Jul → Dec 2012 | migraine disorder | Allergan | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MK-1602 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01657370 ↗ |
| Route | Oral | “Dosage form is film coated tablet for oral administration.” NCT01613248 ↗ |